Literature DB >> 7985493

Neuronal and glial tau-positive inclusions in diverse neurologic diseases share common phosphorylation characteristics.

T Iwatsubo1, M Hasegawa, Y Ihara.   

Abstract

Tau accumulating as paired helical filaments (PHF) in Alzheimer's disease brain is considered to be abnormally phosphorylated on distinct sites. To compare the phosphorylation state of tau-positive neuronal inclusions among diverse neurologic diseases, we have probed these lesions with three well-defined PHF/tau monoclonals, C5, M4 and tau 1, that most likely recognize three proline-directed phosphorylation sites in PHF-tau. In Alzheimer's disease brain all three monoclonals intensely immunostained intracellular neurofibrillary tangles, neuropil threads, senile plaque neurites, and "pretangle neurons" in a phosphorylation-dependent manner. They also stained, in the same manner, Pick bodies in Pick's disease, and neurofibrillary tangles and neuropil threads in various tangle-forming neurologic diseases. In most of these diseases (including Pick's disease, progressive supranuclear palsy, subacute sclerosing panencephalitis, and Alzheimer's disease) astrocytes and oligodendrocytes were found to contain tau-positive inclusions which showed the same immunocytochemical characteristics. Thus, the widely occurring tau-positive inclusions share common phosphorylation characteristics irrespective of underlying diseases or cell types.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7985493     DOI: 10.1007/BF00294505

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  41 in total

1.  Sharing of specific antigens by degenerating neurons in Pick's disease and Alzheimer's disease.

Authors:  C G Rasool; D J Selkoe
Journal:  N Engl J Med       Date:  1985-03-14       Impact factor: 91.245

2.  Immunocytochemistry of neurofibrillary tangles in dementia pugilistica and Alzheimer's disease: evidence for common genesis.

Authors:  G W Roberts
Journal:  Lancet       Date:  1988 Dec 24-31       Impact factor: 79.321

3.  Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau.

Authors:  E M Mandelkow; G Drewes; J Biernat; N Gustke; J Van Lint; J R Vandenheede; E Mandelkow
Journal:  FEBS Lett       Date:  1992-12-21       Impact factor: 4.124

4.  Appearance of paired nucleated, Tau-positive glia in patients with progressive supranuclear palsy brain tissue.

Authors:  T Yamada; P L McGeer; E G McGeer
Journal:  Neurosci Lett       Date:  1992-01-20       Impact factor: 3.046

5.  Neuronal cdc2-like kinase: a cdc2-related protein kinase with predominantly neuronal expression.

Authors:  M R Hellmich; H C Pant; E Wada; J F Battey
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

6.  Glial fibrillary tangles with straight tubules in the brains of patients with progressive supranuclear palsy.

Authors:  M Nishimura; Y Namba; K Ikeda; M Oda
Journal:  Neurosci Lett       Date:  1992-08-31       Impact factor: 3.046

7.  Progressive supranuclear palsy: extensive neuropil threads in addition to neurofibrillary tangles. Very similar antigenicity of subcortical neuronal pathology in progressive supranuclear palsy and Alzheimer's disease.

Authors:  A Probst; D Langui; C Lautenschlager; J Ulrich; J P Brion; B H Anderton
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

8.  Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain.

Authors:  M Hasegawa; M Morishima-Kawashima; K Takio; M Suzuki; K Titani; Y Ihara
Journal:  J Biol Chem       Date:  1992-08-25       Impact factor: 5.157

9.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

10.  Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type.

Authors:  S Flament; A Delacourte; M Verny; J J Hauw; F Javoy-Agid
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

View more
  27 in total

1.  Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models.

Authors:  Preeti J Khandelwal; Sonya B Dumanis; Alexander M Herman; G William Rebeck; Charbel E-H Moussa
Journal:  Mol Cell Neurosci       Date:  2011-09-14       Impact factor: 4.314

Review 2.  Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases.

Authors:  G Brent Irvine; Omar M El-Agnaf; Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

3.  The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies.

Authors:  Jeremy G Stone; Sandra L Siedlak; Massimo Tabaton; Asao Hirano; Rudy J Castellani; Corrado Santocanale; George Perry; Mark A Smith; Xiongwei Zhu; Hyoung-gon Lee
Journal:  J Neuropathol Exp Neurol       Date:  2011-07       Impact factor: 3.685

4.  Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: differentiation from progressive supranuclear palsy.

Authors:  M B Feany; H Ksiezak-Reding; W K Liu; I Vincent; S H Yen; D W Dickson
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

5.  Neurofibrillary tangle predominant form of senile dementia of Alzheimer type: a rare subtype in very old subjects.

Authors:  C Bancher; K A Jellinger
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 6.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

7.  Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy.

Authors:  M Pérez; J M Valpuesta; E M de Garcini; C Quintana; M Arrasate; J L López Carrascosa; A Rábano; J García de Yébenes; J Avila
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

Review 8.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

9.  Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease.

Authors:  Elyse Rosa; Sujeivan Mahendram; Yazi D Ke; Lars M Ittner; Stephen D Ginsberg; Margaret Fahnestock
Journal:  Neurobiol Aging       Date:  2016-08-31       Impact factor: 4.673

Review 10.  Drosophila melanogaster as a model organism of brain diseases.

Authors:  Astrid Jeibmann; Werner Paulus
Journal:  Int J Mol Sci       Date:  2009-02-02       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.